查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1990267

良性前列腺增生（BPH）治療市場：依藥物類別、非專利狀態、劑型及通路分類－2026-2032年全球市場預測

Benign Prostatic Hypertrophy Drugs Market by Drug Class, Generic Status, Dosage Form, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，良性前列腺增生 (BPH) 治療市場價值將達到 58.9 億美元，到 2026 年將成長至 62.9 億美元，到 2032 年將達到 95.9 億美元，複合年成長率為 7.20%。

主要市場統計數據
基準年 2025 58.9億美元
預計年份：2026年 62.9億美元
預測年份 2032 95.9億美元
複合年成長率 (%) 7.20%

對重塑良性前列腺增生 (BPH) 藥物治療方法和獲取趨勢的臨床、監管和商業性因素進行了權威概述。

本執行摘要概述了良性前列腺增生 (BPH) 藥物治療領域複雜的臨床、監管和商業性環境，重點闡述了人口老化、臨床指南不斷更新以及供應鏈現狀變化之間的相互作用。本文將目前的治療現狀置於藥物安全性監測日益加強、專利到期以及對兼顧療效和耐受性的聯合治療的日益關注等背景下進行分析。後續說明整合了活性成分組合、處方實踐和分銷模式的最新趨勢，為評估政策、投資或研發決策的相關人員提供了一個統一的觀點。

本文簡要探討了良性前列腺增生 (BPH) 治療策略、取得途徑和競爭格局正在發生的重大臨床、商業和監管變化。

良性攝護腺增生 (BPH) 治療市場的模式正在經歷一場變革，這反映了醫療保健、藥物研發和病人參與領域的更廣泛變化。關鍵的轉變包括從單一療法模式轉向聯合治療，以尋求在症狀控制和疾病進展預防方面產生協同效應。同時，植物療法證據的日趨成熟以及將真實世界證據納入療效比較評估，正在拓展治療選擇並影響處方行為。

評估 2025 年關稅措施對良性前列腺增生 (BPH) 藥物的採購、生產韌性和商業性準備的影響。

2025年關稅及相關貿易政策措施的實施，進一步加劇了醫藥供應鏈的複雜性，並對生產決策、籌資策略和庫存管理產生連鎖反應。關稅可能增加進口原料藥和成品藥的接收成本，迫使生產商重新評估其採購管道、最佳化生產基地並與供應商重新談判合約。在價格和報銷受到嚴格監管的地區，這些額外的成本壓力可能會擠壓利潤空間，促使企業提高效率，並加快本地化生產以降低對外貿易摩擦的風險。

將藥物類別、一般化狀態、分銷管道和劑型特徵與處方行為、獲取途徑和產品策略聯繫起來的詳細細分分析。

治療領域細分揭示了不同的臨床和商業性動態，這對於貫穿研發、商業化和分銷的策略規劃至關重要。依藥物類別分類，產品組合涵蓋5α-還原酶抑制劑、α阻斷劑、聯合治療和植物療法。 5α-還原酶抑制劑類別的特點是具有獨特的活性成分，例如度他雄胺和非那雄胺，每種成分都具有不同的藥物動力學特性，並且現有的臨床數據會影響處方醫生的選擇。 α阻斷劑包括多種藥物，例如阿夫唑嗪、多沙唑嗪、西洛多辛、Tamsulosin和特拉唑嗪，其選擇性光譜和不利事件會影響針對特定患者表現型的治療方法。聯合治療包括5α-還原酶抑制劑與選擇性α阻斷劑的組合，常見的組合包括度他雄胺和Tamsulosin，以及非那雄胺和Tamsulosin。這些聯合治療旨在既能即時緩解症狀，又能長期縮小前列腺體積。對於尋求輔助或替代療法的患者，以及希望將患者意願納入共同決策的臨床醫生而言，使用BETA-植甾醇、非洲臀果木和鋸棕櫚等草藥的替代療法仍然是重要的選擇。

區域概況重點介紹了監管多樣性、報銷框架和醫療保健基礎設施如何在全球範圍內造成不同的獲取和採用模式。

區域差異顯著影響藥物的研發、核准、報銷以及最終患者獲得治療的機會，每個地區都有其獨特的監管、支付方和臨床實踐現狀。在美洲，治療方法的多樣性——從公共資助的國家計畫到以私人保險為主的體系——影響著談判方式、競標實踐、藥物納入清單的時間安排，以及聯合治療和新劑型的引入。報銷機制和臨床指引建議相互作用，決定新證據轉化為標準實務的速度。

對成熟新興企業在產品差異化和市場定位方面所採取的競爭策略和策略措施進行分析概述。

此治療領域的競爭動態呈現出兩極化的態勢：既有擁有雄厚品牌資產的老牌製藥公司，也有在細分市場中尋求立足之地的靈活非專利和專科藥公司。現有研發公司繼續利用其臨床記錄、醫生關係和品牌知名度，而非專利藥生產商則專注於成本競爭力、穩定的供應以及與經銷商和採購聯盟的合作。創新體現在固定劑量組合藥物的核准、緩釋製劑的改進以及旨在提高患者用藥依從性和持續性的患者支持服務等領域。

一系列可操作且有影響力的策略措施，旨在幫助製藥公司、支付方和經銷商提高良性前列腺增生症治療方案的韌性、臨床價值和可近性。

產業領導者應優先考慮一系列旨在增強韌性、臨床意義和商業性差異化的措施。首先，將臨床開發和上市後證據的生成與真實世界臨床實踐中的療效和安全性終點相結合，可以增強產品對支付方和處方醫生的價值吸引力。在常規臨床實踐中展示聯合治療和新製劑的具體益處，有助於將其納入指南並獲得支付方的認可。其次，最佳化供應鏈結構，減少對單一來源的依賴以及貿易相關衝擊的影響，可以確保產品供應的穩定性。相關策略包括區域性生產夥伴關係、關鍵中間體的雙重採購以及與主要經銷商的聯合庫存管理。

對調查方法進行透明的總結，說明定性研究和二手研究的整合、資料檢驗技術以及局限性，以支持可重複性和策略性解釋。

本報告的分析整合了多種研究途徑，以確保提供可靠且可操作的見解。主要研究內容包括對臨床專家、處方集決策者、採購經理和專科藥劑師進行結構化訪談，以了解當前的實踐模式和支付者的期望。此外，還對生產製造和供應鏈高管進行了訪談，以了解籌資策略和產能的考量，補充了這些定性資訊。次要研究則納入了監管文件、臨床試驗註冊數據和同行評審的臨床文獻，以全面檢驗療效、安全性和指南趨勢。

這是一份權威的綜合分析報告，它提取了對相關人員的影響，並概述了將新趨勢轉化為永續的臨床和商業性優勢所需的策略工具。

總之，良性前列腺增生（BPH）的治療格局正受到多種因素的共同影響而重塑。具體而言，這些因素包括臨床上對聯合治療的偏好轉變、監管機構對安全性和長期治療效果日益重視，以及智慧財產權變化和供應鏈波動帶來的商業性壓力。這些趨勢既給致力於在改善患者照護的同時維持永續商業模式的相關人員帶來了挑戰，也帶來了機會。生產和供應鏈的韌性、策略性證據的產生以及以患者為中心的參與，將成為決定哪些產品和公司能夠取得持久成功的關鍵因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 良性攝護腺增生治療藥物市場：依藥物類別分類

  • 5α-還原酶抑制劑
    • 度他雄胺
    • 非那雄胺
  • α受體阻斷劑
    • 阿夫唑嗪
    • 多沙唑嗪
    • 西洛多辛
    • Tamsulosin
    • 特拉唑嗪
  • 聯合治療
    • 度他雄胺+Tamsulosin
    • 非那雄胺+Tamsulosin
  • 植物療法
    • BETA-谷甾醇
    • 非洲臀果木
    • 鋸棕櫚

第9章 良性前列腺增生（BPH）治療藥物市場：非專利現狀

  • 品牌商品
    • 阿伏達特
    • 弗洛馬克斯
    • 賈林
    • 保列治
  • 非專利的

第10章 良性攝護腺增生治療藥物市場分析

  • 膠囊
    • 緩釋
    • 立即發布
  • 口服液
  • 藥片
    • 緩釋
    • 立即發布

第11章 良性攝護腺增生治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 良性攝護腺增生（BPH）治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 良性攝護腺增生治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 良性攝護腺增生治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國良性攝護腺增生（BPH）治療市場

第16章：中國良性攝護腺增生治療藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc
  • Astellas Pharma Inc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc
  • GlaxoSmithKline plc
  • Ipsen SA
  • Johnson & Johnson
  • Kaken Pharmaceutical Co Ltd
  • Kissei Pharmaceutical Co Ltd
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc
Product Code: MRR-CB04E056547E

The Benign Prostatic Hypertrophy Drugs Market was valued at USD 5.89 billion in 2025 and is projected to grow to USD 6.29 billion in 2026, with a CAGR of 7.20%, reaching USD 9.59 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.89 billion
Estimated Year [2026] USD 6.29 billion
Forecast Year [2032] USD 9.59 billion
CAGR (%) 7.20%

An authoritative orientation to the clinical, regulatory, and commercial factors reshaping therapeutic approaches and access dynamics for benign prostatic hypertrophy drugs

This executive summary introduces the complex clinical, regulatory, and commercial environment surrounding pharmacologic management of benign prostatic hypertrophy, emphasizing the confluence of aging demographics, evolving clinical guidelines, and shifting supply chain realities. It situates the therapeutic landscape within an era of intensified scrutiny over drug safety profiles, patent expirations for legacy agents, and rising interest in combination regimens that aim to balance efficacy with tolerability. The narrative that follows synthesizes recent developments in active ingredient portfolios, prescribing practices, and distribution modalities to provide a cohesive perspective for stakeholders evaluating policy, investment, or R&D decisions.

The introduction recognizes the heterogeneity of patient journeys-from initial symptom management to advanced intervention-and underscores how therapeutic choice is increasingly influenced by comorbidity management, polypharmacy concerns, and patient preferences for convenience and quality of life. Clinical guidelines continue to refine criteria for intervention, while payers and providers reassess treatment pathways to optimize outcomes and cost-effectiveness. In parallel, innovation is concentrated on improving adherence through formulation science and on identifying complementary therapies that mitigate adverse effects of standard agents. This section frames the subsequent analysis by highlighting the principal forces that are likely to drive strategic priorities across industry, clinical practice, and regulatory spheres.

A concise exploration of the pivotal clinical, commercial, and regulatory transitions that are redefining therapeutic strategies, access, and competitive dynamics for BPH treatments

The landscape for benign prostatic hypertrophy therapeutics has undergone transformative shifts that reflect broader changes across healthcare delivery, drug development, and patient engagement. Key shifts include a move from single-agent paradigms toward combination strategies that seek synergistic gains in symptom control and disease progression mitigation. This is complemented by a parallel maturation of evidence around phytotherapeutic options and the integration of real-world evidence into comparative effectiveness assessments, which together broaden therapeutic choice and influence prescribing behavior.

Another transformative element is the rapid digitization of the patient journey, which has altered how prescriptions are accessed, refilled, and monitored. Telehealth consultations and digital adherence tools are increasingly common, prompting manufacturers and distributors to re-evaluate channels for patient support programs and post-marketing surveillance. Regulatory environments have also evolved, with authorities emphasizing pharmacovigilance and clearer benefit-risk communication, particularly for agents with long-term exposure in older populations. In addition, intellectual property transitions and the rise of high-quality generics are intensifying competition and prompting lifecycle strategies focused on formulation improvements, combination approvals, and line extensions. Collectively, these shifts compel manufacturers, payers, and clinicians to reassess clinical value propositions and to prioritize interventions that demonstrably improve long-term patient outcomes while maintaining affordability and access.

An assessment of how 2025 tariff measures influenced pharmaceutical sourcing, manufacturing resilience, and commercial readiness for benign prostatic hypertrophy therapeutics

The imposition of tariffs and related trade policy measures in 2025 introduced incremental complexity into the supply chain for pharmaceuticals, with cascading effects on manufacturing decisions, procurement strategies, and inventory management. Tariffs can increase landed costs for imported active pharmaceutical ingredients and finished dosage forms, prompting manufacturers to review sourcing options, re-optimize production footprints, and renegotiate supplier contracts. In jurisdictions where pricing and reimbursement are tightly regulated, these added cost pressures can compress margins, catalyze efficiency drives, and accelerate efforts to localize manufacturing to reduce exposure to external trade friction.

Beyond direct cost implications, tariffs have also influenced the cadence of regulatory submissions and contract negotiations. Procurement officers and health systems have increasingly factored geopolitical risk into multi-year supplier agreements and contingency planning, driving a preference for diversified supplier networks and buffer inventories. For manufacturers, the response has included greater emphasis on supply chain resilience through dual sourcing, strategic stockpiling of critical intermediates, and investment in regional production capabilities. Importantly, these adaptations affect more than cost lines; they shape product availability, launch sequencing for new formulations or combination therapies, and the competitive landscape as some firms are better positioned to absorb or mitigate tariff-related disruptions. In sum, tariff dynamics in 2025 acted as an accelerant for strategic realignment across sourcing, manufacturing, and commercialization decisions within the therapeutic area.

In-depth segmentation narrative linking drug classes, generic status, distribution channels, and dosage form attributes to prescribing behavior, access pathways, and product strategies

Segmentation of the therapeutic domain reveals differentiated clinical and commercial dynamics that are essential for strategic planning across development, commercialization, and distribution. Based on drug class, the portfolio spans 5-alpha reductase inhibitors, alpha blockers, combination therapy, and phytotherapy. The 5-alpha reductase inhibitors category is characterized by distinct active molecules such as dutasteride and finasteride, each with divergent pharmacokinetic properties and legacy clinical data that influence prescriber choice. Alpha blockers encompass a spectrum of agents including alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin, where selectivity profiles and adverse event considerations drive therapeutic selection for specific patient phenotypes. Combination therapy options pair a 5-alpha reductase inhibitor with a selective alpha blocker, with commonly observed pairings involving dutasteride plus tamsulosin and finasteride plus tamsulosin; these combinations are positioned to address both immediate symptom relief and longer-term prostate volume reduction. Phytotherapeutic alternatives-such as beta-sitosterol, pygeum, and saw palmetto-remain relevant for patients seeking complementary or alternative approaches and for clinicians who integrate patient preference into shared decision-making.

Based on generic status, the landscape comprises both branded and generic offerings, with branded agents including noted trade names that have historically shaped prescribing habits and promotional approaches. Patent expirations and the ensuing generic entries have prompted lifecycle management strategies among originators, including reformulation, indication consolidation, and patient support initiatives. Based on distribution channel, treatment access is mediated through hospital pharmacies, online pharmacies, and retail pharmacies; each channel has its own dynamics around procurement cycles, patient counseling opportunities, and reimbursement interactions. Based on dosage form, therapeutic presentations include capsules, oral solutions, and tablets, with formulations differentiated by release profile-capsules and tablets are available in extended release and immediate release variants-affecting adherence, dosing convenience, and tolerability profiles. Recognizing these segmentation nuances is critical for aligning product development, commercial messaging, and distribution strategies with clinician needs and patient expectations.

A regional synthesis highlighting how regulatory diversity, reimbursement frameworks, and healthcare infrastructure drive distinct access and adoption patterns across global territories

Regional differences materially shape how therapies are developed, approved, reimbursed, and ultimately accessed by patients, with each geographic area presenting distinct regulatory, payer, and clinical practice realities. In the Americas, healthcare systems vary from publicly funded national programs to predominantly private insurance frameworks, influencing formulary negotiation approaches, tendering practices, and the adoption timeline for combination therapies and novel formulations. Reimbursement mechanisms and clinical guideline endorsements interact to determine how quickly new evidence is translated into changes in standard practice.

In Europe, the Middle East & Africa region, a mosaic of regulatory regimes and reimbursement environments requires tailored market access strategies that account for divergent price controls, varying levels of pharmacovigilance infrastructure, and differing capacities for local manufacturing. This complexity often necessitates regionalized clinical evidence generation and adaptive commercial models that reflect the heterogeneity of payer expectations. In the Asia-Pacific region, high population growth, increasing healthcare investment, and accelerating digital health adoption are creating fertile conditions for expanded access models, greater emphasis on cost-effective generics, and the rapid scaling of e-prescription and online pharmacy channels. Across all regions, local clinical guidelines, demographic trends, and supply chain capabilities are primary determinants of product uptake and long-term positioning.

An analytical overview of competitive approaches and strategic maneuvers by incumbent and emerging companies shaping product differentiation and market positioning

Competitive dynamics in this therapeutic area reflect a mix of established pharmaceutical firms with legacy branded assets and agile generic manufacturers and specialty companies pursuing niche positioning. Incumbent originator companies continue to leverage clinical legacy, physician relationships, and brand recognition, while generics manufacturers focus on cost competitiveness, reliable supply, and partnerships with distributors and procurement consortia. Innovation is observable in areas such as fixed-dose combination approvals, reformulated extended-release products, and patient support services designed to improve adherence and persistence.

Strategic collaborations and licensing arrangements are increasingly prominent as a way to accelerate geographic expansion and to share risk related to manufacturing localization or regulatory submissions. Companies that invest in clinical evidence demonstrating improved outcomes with combination regimens or novel formulations tend to achieve stronger clinician buy-in. At the same time, those that can integrate digital support tools, curated educational content for prescribers, and real-world data capture into their go-to-market strategies create differentiated value propositions that extend beyond price-focused competition. The interplay between brand stewardship and cost-effective manufacturing capability will remain central to competitive performance in the near term.

A set of practical, high-impact strategic moves for manufacturers, payers, and distributors to strengthen resilience, clinical value, and uptake of BPH treatment options

Industry leaders should prioritize a portfolio of actions designed to enhance resilience, clinical relevance, and commercial differentiation. First, aligning clinical development and post-marketing evidence generation with real-world effectiveness and safety endpoints will strengthen value narratives with payers and prescribers. Demonstrating tangible benefits of combination regimens or new formulations in routine care settings will facilitate guideline incorporation and payer acceptance. Second, optimizing supply chain architecture to reduce exposure to single-source dependencies and trade-related shocks will protect product availability; strategies include regional manufacturing partnerships, dual sourcing of key intermediates, and collaborative inventory management with major distributors.

Third, investment in digital patient engagement and adherence technologies should be treated as a core component of product launch and lifecycle programs rather than an adjunct activity, because these tools can materially improve persistence and support outcome-based contracting. Fourth, tailored access strategies that reflect regional regulatory and reimbursement realities-ranging from evidence packages for health technology assessment committees to flexible pricing arrangements-will be essential to unlocking adoption across diverse jurisdictions. Finally, companies should explore targeted alliances with clinical centers and professional societies to co-create educational initiatives that address appropriate patient selection and long-term management, thereby elevating both clinical practice and product uptake.

A transparent methodological synopsis describing qualitative and secondary research integration, data validation approaches, and limitations to support reproducibility and strategic interpretation

The analysis underpinning this report synthesizes multiple research approaches to ensure robust, actionable insights. Primary research elements included structured interviews with clinical experts, formulary decision-makers, procurement leads, and specialty pharmacists to capture contemporary practice patterns and payer expectations. These qualitative inputs were complemented by targeted interviews with manufacturing and supply chain executives to understand sourcing strategies and capacity considerations. Secondary research incorporated regulatory documents, clinical trial registries, and peer-reviewed clinical literature to triangulate efficacy, safety, and guideline trends.

Data integrity was maintained through cross-validation of stakeholder claims against publicly available regulatory communications and clinical evidence. The methodology emphasized transparency in assumptions and documented limitations, including recognition of geographic variability in data availability. Where applicable, synthesis prioritized recent peer-reviewed findings and government-issued guidance to reflect current standards of care and regulatory priorities. Throughout the research process, ethical considerations guided outreach and data handling, and methodological choices were designed to support reproducibility and relevance to strategic decision-making.

A conclusive synthesis that distills implications for stakeholders and outlines the strategic levers necessary to convert emerging trends into sustainable clinical and commercial advantages

In conclusion, the therapeutic landscape for benign prostatic hypertrophy is being reshaped by convergent forces: clinical preferences shifting toward combination strategies, regulatory emphasis on safety and long-term outcomes, and commercial pressures arising from intellectual property transitions and supply chain volatility. These dynamics create both challenges and opportunities for stakeholders seeking to advance patient care while maintaining sustainable commercial models. Resilience in manufacturing and supply, strategic evidence generation, and patient-centric engagement will be the differentiators that determine which products and companies achieve durable success.

Looking ahead, organizations that proactively adapt to regional regulatory nuances, integrate digital adherence solutions, and align clinical development with real-world outcomes will be best positioned to influence standards of care and secure durable partnerships with payers and healthcare systems. Cross-functional collaboration-linking R&D, regulatory affairs, supply chain, and commercial teams-will be essential to translate insight into execution and to ensure that innovations meaningfully improve patient experiences and clinical endpoints.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Benign Prostatic Hypertrophy Drugs Market, by Drug Class

  • 8.1. 5-Alpha Reductase Inhibitors
    • 8.1.1. Dutasteride
    • 8.1.2. Finasteride
  • 8.2. Alpha Blockers
    • 8.2.1. Alfuzosin
    • 8.2.2. Doxazosin
    • 8.2.3. Silodosin
    • 8.2.4. Tamsulosin
    • 8.2.5. Terazosin
  • 8.3. Combination Therapy
    • 8.3.1. Dutasteride + Tamsulosin
    • 8.3.2. Finasteride + Tamsulosin
  • 8.4. Phytotherapy
    • 8.4.1. Beta-Sitosterol
    • 8.4.2. Pygeum
    • 8.4.3. Saw Palmetto

9. Benign Prostatic Hypertrophy Drugs Market, by Generic Status

  • 9.1. Branded
    • 9.1.1. Avodart
    • 9.1.2. Flomax
    • 9.1.3. Jalyn
    • 9.1.4. Proscar
  • 9.2. Generic

10. Benign Prostatic Hypertrophy Drugs Market, by Dosage Form

  • 10.1. Capsule
    • 10.1.1. Extended Release
    • 10.1.2. Immediate Release
  • 10.2. Oral Solution
  • 10.3. Tablet
    • 10.3.1. Extended Release
    • 10.3.2. Immediate Release

11. Benign Prostatic Hypertrophy Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Benign Prostatic Hypertrophy Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Benign Prostatic Hypertrophy Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Benign Prostatic Hypertrophy Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Benign Prostatic Hypertrophy Drugs Market

16. China Benign Prostatic Hypertrophy Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc
  • 17.6. Astellas Pharma Inc
  • 17.7. Bayer AG
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Eli Lilly and Company
  • 17.11. Endo Pharmaceuticals Inc
  • 17.12. GlaxoSmithKline plc
  • 17.13. Ipsen S.A
  • 17.14. Johnson & Johnson
  • 17.15. Kaken Pharmaceutical Co Ltd
  • 17.16. Kissei Pharmaceutical Co Ltd
  • 17.17. Merck & Co Inc
  • 17.18. Novartis AG
  • 17.19. Pfizer Inc
  • 17.20. Sanofi S.A
  • 17.21. Sun Pharmaceutical Industries Ltd
  • 17.22. Teva Pharmaceutical Industries Ltd
  • 17.23. Viatris Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018